FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887352196> ?p ?o ?g. }

• W2887352196 endingPage "362" @default.
• W2887352196 startingPage "355" @default.
• W2887352196 abstract "Trastuzumab with cisplatin and fluoropyrimidine is the standard treatment in metastatic HER2-positive gastric or gastroesophageal (GE) junction adenocarcinoma; however, there is limited data on the efficacy of trastuzumab in combination with a three-drug regimen in this setting. We examined the efficacy and safety of modified docetaxel, cisplatin and 5 fluorouracil (mDCF) plus trastuzumab in a single-arm multicenter phase II trial.Previously untreated patients with HER2-positive metastatic gastric or GE junction adenocarcinoma were treated with mDCF and trastuzumab every 2 weeks. The primary endpoint was 6-month progression-free survival (PFS); secondary endpoints included objective response rate, overall survival (OS), and toxicity.We enrolled 26 patients with metastatic HER2-positive gastric or GE junction adenocarcinoma between February 2011 and June 2015. The median age of patients was 62 years; 96% had a Karnofsky performance status equal to or greater than 80%. With a median follow-up of 25.4 months, the 6-month PFS was 73% (95% CI 51-86%). The objective response rate was 65%, the median PFS was 13 months (95% CI 6.4-20.7) and the median OS was 24.9 months (95% CI 14.4-42.5). Grade 3/4 toxicities included neutropenia (42%), fatigue (23%), and hypophosphatemia (15%). There were no episodes of febrile neutropenia.The combination of mDCF and trastuzumab is effective and safe in patients with metastatic HER2-positive gastric or GE junction adenocarcinoma and can be considered as an option for selected patients. This trial is registered at ClinicalTrials.gov, number NCT00515411." @default.
• W2887352196 created "2018-08-22" @default.
• W2887352196 creator A5004669792 @default.
• W2887352196 creator A5009446517 @default.
• W2887352196 creator A5009582351 @default.
• W2887352196 creator A5019892202 @default.
• W2887352196 creator A5022022603 @default.
• W2887352196 creator A5031045426 @default.
• W2887352196 creator A5033125884 @default.
• W2887352196 creator A5035865205 @default.
• W2887352196 creator A5037092952 @default.
• W2887352196 creator A5038396374 @default.
• W2887352196 creator A5045756365 @default.
• W2887352196 creator A5052433892 @default.
• W2887352196 creator A5061301127 @default.
• W2887352196 creator A5065895776 @default.
• W2887352196 creator A5068026508 @default.
• W2887352196 creator A5069929201 @default.
• W2887352196 creator A5070003582 @default.
• W2887352196 creator A5072581354 @default.
• W2887352196 creator A5074144766 @default.
• W2887352196 creator A5083487197 @default.
• W2887352196 creator A5083619102 @default.
• W2887352196 creator A5089202777 @default.
• W2887352196 date "2018-08-07" @default.
• W2887352196 modified "2023-09-26" @default.
• W2887352196 title "Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer" @default.
• W2887352196 cites W1875373156 @default.
• W2887352196 cites W1964230131 @default.
• W2887352196 cites W1996862533 @default.
• W2887352196 cites W2082145086 @default.
• W2887352196 cites W2087202011 @default.
• W2887352196 cites W2100439220 @default.
• W2887352196 cites W2102508255 @default.
• W2887352196 cites W2122866527 @default.
• W2887352196 cites W2125201819 @default.
• W2887352196 cites W2126547130 @default.
• W2887352196 cites W2136197678 @default.
• W2887352196 cites W2139248078 @default.
• W2887352196 cites W2151217508 @default.
• W2887352196 cites W2177986043 @default.
• W2887352196 cites W2191279851 @default.
• W2887352196 cites W223909586 @default.
• W2887352196 cites W2252468824 @default.
• W2887352196 cites W2305101902 @default.
• W2887352196 cites W2479717569 @default.
• W2887352196 cites W2612043425 @default.
• W2887352196 cites W2613362156 @default.
• W2887352196 cites W2620590125 @default.
• W2887352196 cites W2764165143 @default.
• W2887352196 cites W2767612092 @default.
• W2887352196 cites W902906317 @default.
• W2887352196 doi "https://doi.org/10.1007/s10120-018-0861-7" @default.
• W2887352196 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6784321" @default.
• W2887352196 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30088161" @default.
• W2887352196 hasPublicationYear "2018" @default.
• W2887352196 type Work @default.
• W2887352196 sameAs 2887352196 @default.
• W2887352196 citedByCount "11" @default.
• W2887352196 countsByYear W28873521962019 @default.
• W2887352196 countsByYear W28873521962020 @default.
• W2887352196 countsByYear W28873521962021 @default.
• W2887352196 countsByYear W28873521962022 @default.
• W2887352196 countsByYear W28873521962023 @default.
• W2887352196 crossrefType "journal-article" @default.
• W2887352196 hasAuthorship W2887352196A5004669792 @default.
• W2887352196 hasAuthorship W2887352196A5009446517 @default.
• W2887352196 hasAuthorship W2887352196A5009582351 @default.
• W2887352196 hasAuthorship W2887352196A5019892202 @default.
• W2887352196 hasAuthorship W2887352196A5022022603 @default.
• W2887352196 hasAuthorship W2887352196A5031045426 @default.
• W2887352196 hasAuthorship W2887352196A5033125884 @default.
• W2887352196 hasAuthorship W2887352196A5035865205 @default.
• W2887352196 hasAuthorship W2887352196A5037092952 @default.
• W2887352196 hasAuthorship W2887352196A5038396374 @default.
• W2887352196 hasAuthorship W2887352196A5045756365 @default.
• W2887352196 hasAuthorship W2887352196A5052433892 @default.
• W2887352196 hasAuthorship W2887352196A5061301127 @default.
• W2887352196 hasAuthorship W2887352196A5065895776 @default.
• W2887352196 hasAuthorship W2887352196A5068026508 @default.
• W2887352196 hasAuthorship W2887352196A5069929201 @default.
• W2887352196 hasAuthorship W2887352196A5070003582 @default.
• W2887352196 hasAuthorship W2887352196A5072581354 @default.
• W2887352196 hasAuthorship W2887352196A5074144766 @default.
• W2887352196 hasAuthorship W2887352196A5083487197 @default.
• W2887352196 hasAuthorship W2887352196A5083619102 @default.
• W2887352196 hasAuthorship W2887352196A5089202777 @default.
• W2887352196 hasBestOaLocation W28873521961 @default.
• W2887352196 hasConcept C121608353 @default.
• W2887352196 hasConcept C126322002 @default.
• W2887352196 hasConcept C141071460 @default.
• W2887352196 hasConcept C143998085 @default.
• W2887352196 hasConcept C203092338 @default.
• W2887352196 hasConcept C2775930923 @default.
• W2887352196 hasConcept C2776694085 @default.
• W2887352196 hasConcept C2777063308 @default.
• W2887352196 hasConcept C2778850193 @default.
• W2887352196 hasConcept C2779786085 @default.

• next